TEVA - Teva Pharmaceutical Industries Ltd Stock Price, Fair Value and News

17.10USD+0.30 (+1.79%)Market Closed

Market Summary

USD17.10+0.30

Market Closed

1.79%

TEVA Alerts

1 major insider sales recently.

TEVA Stock Price

View Fullscreen

TEVA RSI Chart

TEVA Valuation

Market Cap

19.2B

Price/Earnings (Trailing)

-38.83

Price/Sales (Trailing)

1.2

EV/EBITDA

56.89

Price/Free Cashflow

13.83

TEVA Price/Sales (Trailing)

TEVA Profitability

EBT Margin

-5.22%

Return on Equity

-6.79%

Return on Assets

-1.16%

Free Cashflow Yield

7.23%

TEVA Fundamentals

TEVA Revenue

Revenue (TTM)

16.0B

Rev. Growth (Yr)

4.32%

Rev. Growth (Qtr)

-14.31%

TEVA Earnings

Earnings (TTM)

-494.5M

Earnings Growth (Yr)

36.82%

Earnings Growth (Qtr)

-131.2%

Breaking Down TEVA Revenue

Last 7 days

1.7%

Last 30 days

5.2%

Last 90 days

23.8%

Trailing 12 Months

103.1%

How does TEVA drawdown profile look like?

TEVA Financial Health

Current Ratio

0.89

TEVA Investor Care

Shares Dilution (1Y)

0.72%

Diluted EPS (TTM)

-0.44

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	16.0B	0	0	0
2023	14.9B	15.0B	15.3B	15.8B
2022	15.6B	15.4B	15.1B	14.9B
2021	16.3B	16.3B	16.2B	15.9B
2020	17.1B	16.8B	16.7B	16.7B
2019	17.5B	17.1B	16.8B	16.9B
2018	21.7B	20.5B	19.3B	18.3B
2017	22.7B	23.4B	23.5B	22.4B
2016	19.5B	19.6B	20.3B	21.9B
2015	20.3B	20.2B	19.9B	19.7B
2014	20.4B	20.5B	20.5B	20.3B
2013	20.2B	20.1B	20.2B	20.3B
2012	19.2B	20.0B	20.6B	20.3B
2011	16.5B	17.0B	17.1B	18.3B
2010	16.6B	17.0B	17.7B	16.1B
2009	11.7B	12.2B	12.9B	16.1B
2008	9.8B	10.2B	10.7B	11.1B
2007	0	0	0	9.4B

Get all data in R, Python etc through our Historical Stock Data APIs

About Teva Pharmaceutical Industries Ltd

Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. The company offers sterile products, hormones, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams. It also manufactures and sells active pharmaceutical ingredients, as well as provides contract manufacturing services; and operates an out-licensing platform that offers a portfolio of products to other pharmaceutical companies. In addition, it focuses on the central nervous system (CNS), pain, respiratory, and oncology areas. The company's products portfolio in the CNS field comprises Copaxone for the treatment of relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine in adults; and AUSTEDO for the treatment of neurodegenerative and movement disorders associated with Huntington's disease and tardive dyskinesia; respiratory therapeutic area includes ProAir RespiClick, QVAR, ProAir Digihaler, AirDuo Digihaler, ArmonAir Digihaler, BRALTUS, CINQAIR/CINQAERO, DuoResp Spiromax, and AirDuo RespiClick/ArmonAir RespiClick for the treatment of asthma and chronic obstructive pulmonary disease; and oncology therapeutic field consists of Bendeka, Treanda, Granix, Trisenox, Lonquex, and Tevagrastim/Ratiograstim. Teva Pharmaceutical Industries Limited has a collaboration MedinCell for the development and commercialization of multiple long-acting injectable products, a risperidone suspension for the treatment of patients with schizophrenia. The company was founded in 1901 and is headquartered in Tel Aviv, Israel.

CEO	Mr. Richard D. Francis
WEBSITE	tevapharm.com
INDUSTRY	Pharmaceuticals
EMPLOYEES	34004

Teva Pharmaceutical Industries Ltd Frequently Asked Questions

What is the ticker symbol for Teva Pharmaceutical Industries Ltd? What does TEVA stand for in stocks?

TEVA is the stock ticker symbol of Teva Pharmaceutical Industries Ltd. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Teva Pharmaceutical Industries Ltd (TEVA)?

As of Fri Jul 26 2024, market cap of Teva Pharmaceutical Industries Ltd is 19.2 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of TEVA stock?

You can check TEVA's fair value in chart for subscribers.

Is Teva Pharmaceutical Industries Ltd a good stock to buy?

The fair value guage provides a quick view whether TEVA is over valued or under valued. Whether Teva Pharmaceutical Industries Ltd is cheap or expensive depends on the assumptions which impact Teva Pharmaceutical Industries Ltd's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for TEVA.

What is Teva Pharmaceutical Industries Ltd's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Jul 26 2024, TEVA's PE ratio (Price to Earnings) is -38.83 and Price to Sales (PS) ratio is 1.2. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. TEVA PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Teva Pharmaceutical Industries Ltd's stock?

In the past 10 years, Teva Pharmaceutical Industries Ltd has provided -0.101 (multiply by 100 for percentage) rate of return.